[1]
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T, Wu MH, Saji TT, Pahl E, American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017 Apr 25:135(17):e927-e999. doi: 10.1161/CIR.0000000000000484. Epub 2017 Mar 29
[PubMed PMID: 28356445]
[2]
Saguil A, Fargo M, Grogan S. Diagnosis and management of kawasaki disease. American family physician. 2015 Mar 15:91(6):365-71
[PubMed PMID: 25822554]
[3]
Vervoort D, Donné M, Van Gysel D. Pitfalls in the diagnosis and management of Kawasaki disease: An update for the pediatric dermatologist. Pediatric dermatology. 2018 Nov:35(6):743-747. doi: 10.1111/pde.13620. Epub 2018 Oct 18
[PubMed PMID: 30338568]
[4]
Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circulation journal : official journal of the Japanese Circulation Society. 2014
[PubMed PMID: 25241888]
[5]
Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics. 2015 Sep:136(3):e609-14. doi: 10.1542/peds.2015-0950. Epub 2015 Aug 24
[PubMed PMID: 26304824]
[6]
Sundel RP. Kawasaki disease. Rheumatic diseases clinics of North America. 2015:41(1):63-73, viii. doi: 10.1016/j.rdc.2014.09.010. Epub
[PubMed PMID: 25399940]
[7]
Matsubara T. Infliximab for the treatment of Kawasaki disease. Pediatrics international : official journal of the Japan Pediatric Society. 2018 Sep:60(9):775. doi: 10.1111/ped.13663. Epub
[PubMed PMID: 30255976]
[9]
Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clinical and experimental immunology. 2011 May:164 Suppl 1(Suppl 1):20-2. doi: 10.1111/j.1365-2249.2011.04361.x. Epub
[PubMed PMID: 21447126]
[10]
Rowley AH, Baker SC, Shulman ST, Garcia FL, Fox LM, Kos IM, Crawford SE, Russo PA, Hammadeh R, Takahashi K, Orenstein JM. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PloS one. 2008 Feb 13:3(2):e1582. doi: 10.1371/journal.pone.0001582. Epub 2008 Feb 13
[PubMed PMID: 18270572]
[12]
Marchesi A, Tarissi de Jacobis I, Rigante D, Rimini A, Malorni W, Corsello G, Bossi G, Buonuomo S, Cardinale F, Cortis E, De Benedetti F, De Zorzi A, Duse M, Del Principe D, Dellepiane RM, D'Isanto L, El Hachem M, Esposito S, Falcini F, Giordano U, Maggio MC, Mannarino S, Marseglia G, Martino S, Marucci G, Massaro R, Pescosolido C, Pietraforte D, Pietrogrande MC, Salice P, Secinaro A, Straface E, Villani A. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Italian journal of pediatrics. 2018 Aug 30:44(1):102. doi: 10.1186/s13052-018-0536-3. Epub 2018 Aug 30
[PubMed PMID: 30157897]
[14]
Jindal AK, Indla RT, Pilania RK, Singh S. Non-Exudative Conjunctival Injection With Limbal Sparing: A Pathognomonic Clinical Sign of Kawasaki Disease. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2020 Apr:26(3):e59-e60. doi: 10.1097/RHU.0000000000000883. Epub
[PubMed PMID: 30247222]
[15]
Beken B, Unal S, Cetin M, Gümrük F. The relationship between hematological findings and coronary artery aneurysm in kawasaki disease. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2014 Jun:31(2):199-200. doi: 10.4274/tjh.2013.0241. Epub 2014 Jun 10
[PubMed PMID: 25035683]
[16]
Suddleson EA, Reid B, Woolley MM, Takahashi M. Hydrops of the gallbladder associated with Kawasaki syndrome. Journal of pediatric surgery. 1987 Oct:22(10):956-9
[PubMed PMID: 3316594]
[17]
Sun Q, Zhang J, Yang Y. Gallbladder Hydrops Associated With Kawasaki Disease: A Case Report and Literature Review. Clinical pediatrics. 2018 Mar:57(3):341-343. doi: 10.1177/0009922817696468. Epub 2017 Mar 1
[PubMed PMID: 28952362]
Level 3 (low-level) evidence
[18]
Reddy S, Forbes T, Chintala K. Cardiovascular involvement in Kawaski Disease. Images in paediatric cardiology. 2005 Apr:7(2):1-9
[PubMed PMID: 22368648]
[19]
Tsuda E, Singhal M. Role of imaging studies in Kawasaki disease. International journal of rheumatic diseases. 2018 Jan:21(1):56-63. doi: 10.1111/1756-185X.13210. Epub 2017 Nov 8
[PubMed PMID: 29115035]
[20]
Kahn AM, Budoff MJ, Daniels LB, Jimenez-Fernandez S, Cox AS, Gordon JB, Burns JC. Calcium scoring in patients with a history of Kawasaki disease. JACC. Cardiovascular imaging. 2012 Mar:5(3):264-72. doi: 10.1016/j.jcmg.2011.12.010. Epub
[PubMed PMID: 22421171]
[21]
Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. The Pediatric infectious disease journal. 1998 Dec:17(12):1144-8
[PubMed PMID: 9877364]
[22]
Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics. 1995 Dec:96(6):1057-61
[PubMed PMID: 7491221]
Level 1 (high-level) evidence
[23]
Kim HK, Oh J, Hong YM, Sohn S. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in kawasaki disease. Korean circulation journal. 2011 Jul:41(7):379-84. doi: 10.4070/kcj.2011.41.7.379. Epub 2011 Jul 30
[PubMed PMID: 21860639]
[24]
Yamazaki-Nakashimada MA, Gámez-González LB, Murata C, Honda T, Yasukawa K, Hamada H. IgG levels in Kawasaki disease and its association with clinical outcomes. Clinical rheumatology. 2019 Mar:38(3):749-754. doi: 10.1007/s10067-018-4339-0. Epub 2018 Oct 20
[PubMed PMID: 30343342]
Level 2 (mid-level) evidence
[25]
Fabi M, Corinaldesi E, Pierantoni L, Mazzoni E, Landini C, Bigucci B, Ancora G, Malaigia L, Bodnar T, Di Fazzio G, Lami F, Valletta E, Cicero C, Biasucci G, Iughetti L, Marchetti F, Sogno Valin P, Amarri S, Brusa S, Sprocati M, Maggiore G, Dormi A, Lanzoni P, Donti A, Lanari M. Gastrointestinal presentation of Kawasaki disease: A red flag for severe disease? PloS one. 2018:13(9):e0202658. doi: 10.1371/journal.pone.0202658. Epub 2018 Sep 4
[PubMed PMID: 30180185]
[26]
Nolan BE, Wang Y, Pary PP, Luban NLC, Wong ECC, Ronis T. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease. Transfusion. 2018 Nov:58(11):2564-2571. doi: 10.1111/trf.14879. Epub 2018 Sep 28
[PubMed PMID: 30265742]
[27]
Newburger JW. Kawasaki disease: Medical therapies. Congenital heart disease. 2017 Sep:12(5):641-643. doi: 10.1111/chd.12502. Epub 2017 Jun 5
[PubMed PMID: 28580631]
[28]
Burns JC, Hoshino S, Kobayashi T. Kawasaki disease: an essential comparison of coronary artery aneurysm criteria. The Lancet. Child & adolescent health. 2018 Dec:2(12):840-841. doi: 10.1016/S2352-4642(18)30334-1. Epub 2018 Oct 16
[PubMed PMID: 30337184]
[29]
Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. The Lancet. Child & adolescent health. 2018 Dec:2(12):855-862. doi: 10.1016/S2352-4642(18)30293-1. Epub 2018 Oct 16
[PubMed PMID: 30337183]
[30]
Denby KJ, Clark DE, Markham LW. Management of Kawasaki disease in adults. Heart (British Cardiac Society). 2017 Nov:103(22):1760-1769. doi: 10.1136/heartjnl-2017-311774. Epub 2017 Jul 27
[PubMed PMID: 28751537]
[31]
Williams RV, Wilke VM, Tani LY, Minich LL. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics. 2002 Jan:109(1):E4
[PubMed PMID: 11773572]
[32]
McCandless RT,Minich LL,Tani LY,Williams RV, Does abciximab promote coronary artery remodeling in patients with Kawasaki disease? The American journal of cardiology. 2010 Jun 1
[PubMed PMID: 20494673]
[33]
Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. The Pediatric infectious disease journal. 2011 Oct:30(10):871-6. doi: 10.1097/INF.0b013e318220c3cf. Epub
[PubMed PMID: 21587094]
[34]
Kuijpers TW, Biezeveld M, Achterhuis A, Kuipers I, Lam J, Hack CE, Becker AE, van der Wal AC. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics. 2003 Oct:112(4):986-92
[PubMed PMID: 14523200]
[35]
Gupta-Malhotra M, Gruber D, Abraham SS, Roman MJ, Zabriskie JB, Hudgins LC, Flynn PA, Levine DM, Okorie U, Baday A, Schiller MS, Maturi J, Meehan D, Dyme J, Parker TS, Wittkowski KM, Gersony WM, Cooper RS. Atherosclerosis in survivors of Kawasaki disease. The Journal of pediatrics. 2009 Oct:155(4):572-7. doi: 10.1016/j.jpeds.2009.04.054. Epub
[PubMed PMID: 19595365]
[36]
Gordon JB, Kahn AM, Burns JC. When children with Kawasaki disease grow up: Myocardial and vascular complications in adulthood. Journal of the American College of Cardiology. 2009 Nov 17:54(21):1911-20. doi: 10.1016/j.jacc.2009.04.102. Epub
[PubMed PMID: 19909870]